MEI Pharma Inc

NASDAQ:MEIP

2.75

+0.15 (+5.78%)

Market Cap (Intraday)	328.72M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$4.77 Million
Adjusted EPS	-$0.16

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

MEI Pharma Inc Stock, NASDAQ:MEIP

11455 El Camino Real, Suite 250, San Diego, California 92130

United States of America

Phone: +1.858.369.7100

Number of Employees: 51

http://www.meipharma.com

Description

MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.